Phio Pharmaceuticals
PHIO
10 hedge funds and large institutions have $213K invested in Phio Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
29% less funds holding
Funds holding: 14 → 10 (-4)
49% less capital invested
Capital invested by funds: $415K → $213K (-$202K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$30.2K |
| 2 |
Renaissance Technologies
New York
|
-$22.3K |
| 3 |
VF
Virtu Financial
New York
|
-$11K |
| 4 |
HF
HRT Financial
New York
|
-$10K |
| 5 |
E
Ergoteles
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $62K | -$22.3K | -434 | -22% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $57.5K | -$30.2K | -589 | -29% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $39K | -$154 | -3 | -0.3% |
|
4
Cetera Investment Advisers
Schaumburg,
Illinois
| $27.9K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $8.52K | +$10.9K | +213 | New |
|
6
Two Sigma Investments
New York
| $8.33K | -$410 | -8 | -4% |
|
|
TSS
7
Two Sigma Securities
New York
| $7.33K | -$1.28K | -25 | -12% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2K | -$154 | -3 | -6% |
|
9
Morgan Stanley
New York
| $558 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $35 | – | – | – |
|
11
BlackRock
New York
| $7 | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$11K | -180 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$10K | -169 | Closed |
|
|
E
14
Ergoteles
New York
| – | -$7K | -115 | Closed |
|
15
Balyasny Asset Management
Chicago,
Illinois
| – | -$6K | -93 | Closed |
|
16
JP Morgan Chase
New York
| – | -$410 | -8 | Closed |
|
PHIO Hedge Fund Activity: Q4 2022 in Review
10 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2022, worth a combined $213K — down 49% from $415K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHIO and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $10.9K. The largest seller was Vanguard Group, cutting an estimated $30.2K.
- 10 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2022, down from 14 in Q3 2022.
- Funds reported $213K of Phio Pharmaceuticals stock for Q4 2022, down 49% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -4 holders.
- The largest Phio Pharmaceuticals buyer in Q4 2022 was UBS Group, an estimated $10.9K added.
- The largest Phio Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $30.2K sold.
Based on aggregated 13F filings for Q4 2022.